nach oben

Erschienen in:

26.08.2015 | Research Article

HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma

verfasst von: Manqing Cao, Junrong Gao, Hongyuan Zhou, Jiafei Huang, Abin You, Zhigui Guo, Feng Fang, Wei Zhang, Tianqiang Song, Ti Zhang

Erschienen in: Tumor Biology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Overexpression of CUB domain-containing protein 1 (CDCP1), a transmembrane glycoprotein and major substrate of Src family kinases (SFKs), always indicates unfavorable outcomes in various cancers. The characteristics of CDCP1 in hepatocellular carcinoma (HCC) have not been assessed. Most recently, CDCP1 was identified as a specific target gene of HIF-2α in clear cell renal carcinoma (CC-RCC). However, considering the role of HIF-2α in the progression of HCC is highly controversial, it is necessary to figure out whether HIF-2α and CDCP1 play a significant part in the metastasis of HCC. Our results showed that HIF-2α and CDCP1 were both induced by hypoxia, and the activation of CDCP1 was HIF-2α dependent. CDCP1 was governed by HIF-2α at mRNA and protein levels in HCC cell lines. Moreover, knocking down of HIF-2α not only inhibited cell invasion but also impaired the expression of Tyr³¹¹ phosphorylation of protein kinase Cδ (PKCδ) which is a downstream factor of CDCP1 and has been reported to induce malignant migration in various tumors. Analysis of human HCC samples showed a negative correlation of CDCP1 expression with disease-free survival, and CDCP1 was an independent prognostic factors of disease-free survival. Taken together, these data demonstrated that HIF-2α could promote HCC cell migration by regulating CDCP1, and targeting HIF-2α-CDCP1-PKCδ pathway might be effective to inhibit HCC metastasis.

Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 2009;107(6):1053–62. doi:10.1002/jcb.22214.CrossRefPubMed

Silvan U, Diez-Torre A, Arluzea J, Andrade R, Silio M, Arechaga J. Hypoxia and pluripotency in embryonic and embryonal carcinoma stem cell biology. Differ; Res Biol Divers. 2009;78(2–3):159–68. doi:10.1016/j.diff.2009.06.002.CrossRef

Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N, et al. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology. 2010;51(6):2183–92. doi:10.1002/hep.23597.CrossRefPubMed

Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. Appl Immunohistochem Molec Morphol : AIMM / Off Public Soc Appl Immunohistochem. 2006;14(1):78–82. doi:10.1097/01.pai.0000145182.98577.10.CrossRef

Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res. 2002;62(5):1326–9.PubMed

Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H, et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell. 2006;10(5):413–23. doi:10.1016/j.ccr.2006.08.026.CrossRefPubMed

Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA, Simon MC. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol. 2006;26(9):3514–26. doi:10.1128/MCB.26.9.3514-3526.2006.CrossRefPubMedPubMedCentral

Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85(6):881–90. doi:10.1054/bjoc.2001.2018.CrossRefPubMedPubMedCentral

Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25(13):5675–86. doi:10.1128/MCB.25.13.5675-5686.2005.CrossRefPubMedPubMedCentral

10.

Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, et al. Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 2012;72(9):2285–93. doi:10.1158/0008-5472.CAN-11-3836.CrossRefPubMedPubMedCentral

11.

Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi RY, et al. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. Hepatology. 2013;57(3):1088–97. doi:10.1002/hep.26188.CrossRefPubMedPubMedCentral

12.

Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, Jing S. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol : WJG. 2007;13(23):3176–82.CrossRefPubMedPubMedCentral

13.

Bangoura G, Yang LY, Huang GW, Wang W. Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma. World J Gastroenterol : WJG. 2004;10(4):525–30.CrossRefPubMedPubMedCentral

14.

Liu Y, Yan X, Xu Y, Luo F, Ye J, Yan H, et al. HIFs enhance the migratory and neoplastic capacities of hepatocellular carcinoma cells by promoting EMT. Tumour Biol : J Int Soc Oncodev Biol Med. 2014;35(8):8103–14. doi:10.1007/s13277-014-2056-0.CrossRef

15.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203. doi:10.1016/j.cell.2007.11.025.CrossRefPubMed

16.

Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene. 2001;20(32):4402–8.CrossRefPubMed

17.

Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, et al. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol. 2008;134(12):1363–9. doi:10.1007/s00432-008-0412-4.CrossRefPubMed

18.

Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci U S A. 2011;108(5):1931–6. doi:10.1073/pnas.1011777108.CrossRefPubMedPubMedCentral

19.

Seidel J, Kunc K, Possinger K, Jehn C, Luftner D. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration. Biochem Biophys Res Commun. 2011;414(1):226–32. doi:10.1016/j.bbrc.2011.09.062.CrossRefPubMed

20.

Perry SE, Robinson P, Melcher A, Quirke P, Buhring HJ, Cook GP, et al. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett. 2007;581(6):1137–42. doi:10.1016/j.febslet.2007.02.025.CrossRefPubMed

21.

Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res. 2010;70(12):5136–46. doi:10.1158/0008-5472.CAN-10-0220.CrossRefPubMed

22.

Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci U S A. 2011;108(4):1379–84. doi:10.1073/pnas.1017228108.CrossRefPubMedPubMedCentral

23.

Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol. 2007;27(21):7649–60. doi:10.1128/MCB.01246-07.CrossRefPubMedPubMedCentral

24.

Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci. 2009;100(3):429–33. doi:10.1111/j.1349-7006.2008.01066.x.CrossRefPubMed

25.

Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, et al. Identification of CDCP1 as a hypoxia-inducible factor 2alpha (HIF-2alpha) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci U S A. 2013;110(9):3483–8. doi:10.1073/pnas.1222435110.CrossRefPubMedPubMedCentral

26.

Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005;121(2):271–80. doi:10.1016/j.cell.2005.02.019.CrossRefPubMed

27.

Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y, et al. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol. 2008;172(6):1729–39. doi:10.2353/ajpath.2008.070981.CrossRefPubMedPubMedCentral

28.

Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol : WJG. 2001;7(5):630–6.PubMedPubMedCentral

29.

Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA, et al. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. J Biol Chem. 2012;287(13):9792–803. doi:10.1074/jbc.M111.335448.CrossRefPubMedPubMedCentral

30.

Befani C, Mylonis I, Gkotinakou IM, Georgoulias P, Hu CJ, Simos G, et al. Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells. Int J Biochem Cell Biol. 2013;45(11):2359–68. doi:10.1016/j.biocel.2013.07.025.CrossRefPubMed

31.

He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, et al. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. J Biol Chem. 2010;285(34):26162–73. doi:10.1074/jbc.M109.096453.CrossRefPubMedPubMedCentral

32.

Brenner W, Greber I, Gudejko-Thiel J, Beitz S, Schneider E, Walenta S, et al. Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase. Int J Oncol. 2008;32(5):1125–31.PubMed

33.

Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene. 2003;22(12):1783–94. doi:10.1038/sj.onc.1206220.CrossRefPubMed

34.

Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12(1):9–22. doi:10.1038/nrc3183.

35.

Wu XH, Qian C, Yuan K. Correlations of hypoxia-inducible factor-1alpha/hypoxia-inducible factor-2alpha expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin Med J. 2011;124(1):11–8.PubMed

36.

Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, et al. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008;68(22):9212–20. doi:10.1158/0008-5472.CAN-08-1135.CrossRefPubMed

37.

Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, et al. HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization. Clin Cancer Res : Off J Am Assoc Cancer Res. 2009;15(23):7130–6. doi:10.1158/1078-0432.CCR-09-0223.CrossRef

38.

Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007;11(4):335–47. doi:10.1016/j.ccr.2007.02.006.CrossRefPubMedPubMedCentral

Titel: HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma
verfasst von: Manqing Cao
Junrong Gao
Hongyuan Zhou
Jiafei Huang
Abin You
Zhigui Guo
Feng Fang
Wei Zhang
Tianqiang Song
Ti Zhang
Publikationsdatum: 26.08.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 2/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3527-7

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Identification of expression quantitative trait loci of RPTOR for susceptibility to glioma

Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine

Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145

Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention

The role of lysosome in cell death regulation

A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie